Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM014
- Development stage
- Preclinical
- Lead developer
- Mucommune
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MM014 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by Mucommune for the treatment of solid tumors. As a cell-based immunotherapy, it involves the genetic modification of T cells to express a synthetic receptor designed to recognize and eliminate malignant cells. Currently in the preclinical stage of development, MM014 is part of Mucommune's pipeline focused on leveraging advanced cell engineering to overcome the immunosuppressive environments typically associated with solid malignancies. The specific target antigen for MM014 has not been publicly disclosed.
- Other names
- Mucommune CAR-T cell therapy
Beyond the preview
Go deeper on MM014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM014.